Curium finalizes $1.07 billion term loan B at SOFR plus 400 bps

By Sara Rosenberg

New York, March 22 – Curium Pharma set pricing on its $1.065 billion term loan B due July 2029 at SOFR plus 400 basis points, the low end of the SOFR plus 400 bps to 425 bps talk, according to a market source.

The term loan still has a 0% floor, a par issue price and 101 soft call protection for six months.

JPMorgan Chase Bank is the lead on the deal.

Proceeds will be used to reprice an existing term loan B down from SOFR plus 450 bps with a 0% floor.

Curium is a nuclear medicine company with headquarters in London and Paris.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.